Ironwood Pharmaceuticals Inc 8-K Filing
Ticker: IRWD · Form: 8-K · Filed: Nov 26, 2025 · CIK: 1446847
| Field | Detail |
|---|---|
| Company | Ironwood Pharmaceuticals Inc (IRWD) |
| Form Type | 8-K |
| Filed Date | Nov 26, 2025 |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $136 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Ironwood Pharmaceuticals Inc (ticker: IRWD) to the SEC on Nov 26, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Class A common stock, $0.001 par value IRWD Nasdaq Global Select M); $136 (price as of January 1, 2027, is set to $136. The revised MFP for LINZESS is in line).
How long is this filing?
Ironwood Pharmaceuticals Inc's 8-K filing is 1 pages with approximately 428 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 428 words · 2 min read · ~1 pages · Grade level 11.3 · Accepted 2025-11-26 07:00:30
Key Financial Figures
- $0.001 — ich registered Class A common stock, $0.001 par value IRWD Nasdaq Global Select M
- $136 — price as of January 1, 2027, is set to $136. The revised MFP for LINZESS is in line
Filing Documents
- tm2532096d1_8k.htm (8-K) — 25KB
- 0001104659-25-116217.txt ( ) — 186KB
- irwd-20251125.xsd (EX-101.SCH) — 3KB
- irwd-20251125_lab.xml (EX-101.LAB) — 33KB
- irwd-20251125_pre.xml (EX-101.PRE) — 22KB
- tm2532096d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On November 25, 2025, the U.S. Department of Health and Human Services released the "Maximum Fair Price" ("MFP") for LINZESS (linaclotide), which was selected in the most recent round of government price setting as part of the Inflation Reduction Act of 2022. The MFP for a 30-day equivalent supply of LINZESS, which will become the new Medicare net price as of January 1, 2027, is set to $136. The revised MFP for LINZESS is in line with the expectations of Ironwood Pharmaceuticals, Inc.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ironwood Pharmaceuticals, Inc. Dated: November 26, 2025 By: /s/ Gregory Martini Name: Gregory Martini Title: Senior Vice President, Chief Financial Officer